Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind Phase II, Study of Gemcitabine Alone or in Combination With Pazopanib for Refractory Soft Tissue Sarcoma

NCT01532687 is registered in ClinicalTrials.gov with OHSU Knight Cancer Institute as lead sponsor.

NCT NCT01532687
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01532687 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind Phase II, Study of Gemcitabine Alone or in Combination With Pazopanib for Refractory Soft Tissue Sarcoma
Lead sponsor
OHSU Knight Cancer Institute
Phase
Phase 2
Overall status
Completed
Start date
March 13, 2012
Completion date
October 31, 2019
Enrollment
54 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

adult alveolar soft part sarcoma, adult angiosarcoma, adult desmoplastic small round cell tumor, adult epithelioid hemangioendothelioma, adult epithelioid sarcoma, adult extraskeletal myxoid chondrosarcoma, adult extraskeletal osteosarcoma, adult fibrosarcoma, adult leiomyosarcoma, adult liposarcoma, adult malignant peripheral nerve sheath tumor, adult rhabdomyosarcoma, adult synovial sarcoma, adult undifferentiated pleomorphic sarcoma, malignant adult hemangiopericytoma, recurrent adult soft tissue sarcoma, sarcoma, stage iii adult soft tissue sarcoma ajcc v7, stage iv adult soft tissue sarcoma ajcc v7